Search
Prime Medicine Inc
PRMEAdd to Watchlist
3.155USD
+0.285+9.93%
Close 06/17, 16:00（ET）Quotes delayed by 15 min
570.75MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-17The current earnings forecast score of Prime Medicine Inc is 8.00, ranking 163 out of 388 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 9.00 and a low of 4.25.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
7.036
Target Price
+145.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Prime Medicine Inc
PRME
13
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Prime Medicine Inc's expected revenue for the next quarter?
Prime Medicine Inc's expected revenue is 1.26M.
What is Prime Medicine Inc's price target?
Analysts forecast that Prime Medicine Inc's price target is USD 6.00, with the highest forecast at USD 9.00 and the lowest forecast at USD 4.25.
How have Prime Medicine IncPRME's recent earnings per share performed?
The market expectation was USD -0.28, while Prime Medicine IncPRME's earnings per share (EPS) for the previous quarter was USD -0.26. EPS for the next quarter is expected at USD -0.25.
What is the analyst rating for Prime Medicine Inc?
Based on the ratings of Prime Medicine Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
